23 May '23 at 5:43 pm #59095
Keymaster
PTC Therapeutics (PTCT) announces “topline” results from Vatiquinone MOVE-FA registration-directed trial; to continue development and global commercialization of Upstaza as part of a strategic portfolio prioritization; estimated reductions of approx. 15% in residual 2023 OpEx…
PTCT down 21.8%